National Comprehensive Cancer Network

About NCCN

NCCN Flash Update: NCCN Guidelines®, NCCN Compendium®, and NCCN Templates® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Multiple Myeloma. These NCCN Guidelines® are currently available as Version 3.2017.

  • Myeloma therapy MYEL-D (1 of 2)
    • Reinstated combination bortezomib/thalidomide/dexamethasone (category 1) as a treatment option under other regimens for primary therapy for transplant candidates.
       
  • Myeloma therapy MYEL-D (2 of 2)
    • Moved the following combination regimens from preferred to other regimens for previously treated multiple myeloma:
      • Dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP)
      • Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE)
      • Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib (VTD-PACE)
         
  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 2.2017) to the NCCN Guidelines for Multiple Myeloma, published on October 28, 2016, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

 

NCCN has published the following update to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Multiple Myeloma to reflect the changes in Version 3.2017 of the NCCN Guidelines for Multiple Myeloma:

  • The following chemotherapy order template has been updated and reinstated:
    • MUM19 Bortezomib/Thalidomide/Dexamethasone

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Templates®, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.